Will BIIB Bounce After Today's Disaster?

Insiders' Blog Commentary : Biogen Idec (Nasdaq: BIIB) is looking like a possible dead-cat bounce play after today's 45% sell-off on the Tysabri fallout. The stock is currently at $36.57/share. We view the litigation risk as minimal. Stock should be worth in low-$40s without the drug.

You May Also Be Interested In

• RBC sees a buying opportunity in this software stock after massive selloff
• These 3 Asian stocks are "prime beneficiaries of Muse AI": analyst
• Best oil and gas stocks to buy in case Hormuz reopens: Citi